National Institute for Health and Care Excellence1 天
First targeted treatment to reduce the risk of ALK positive lung cancer returning after ...
First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended ...
National Institute for Health and Care Excellence3 天
In development: Guidance, quality standards and advice
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707] Technology appraisal guidance TBC Ixazomib citrate for ...
National Institute for Health and Care Excellence5 天
Published guidance, NICE advice and quality standards
Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) TA1006 12 September 2024 12 September 2024 Evinacumab for treating homozygous familial hypercholesterolaemia ...
National Institute for Health and Care Excellence5 天
In development: Guidance, quality standards and advice
Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103] Technology appraisal guidance TBC Pembrolizumab with olaparib for treating hormone-relapsed metastatic ...
National Institute for Health and Care Excellence5 天
Dupilumab for treating severe chronic rhinosinusitis with nasal polyposis [ID6480]
For further information on how we select topics for development, please see our page about topic selection ...
National Institute for Health and Care Excellence5 天
Linaclotide acetate for treating Chronic idiopathic constipation [TS ID 12005]
A list of downloadable documents created during development.
National Institute for Health and Care Excellence5 天
Pridopidine for treating Huntington's disease TSID 12052
A list of downloadable documents created during development.
National Institute for Health and Care Excellence5 天
Ustekinumab for the treatment of moderately to severely active Crohn's disease in children ...
A list of downloadable documents created during development.